An assessment of statin safety by hepatologists

David E Cohen; Frank A Anania; Naga Chalasani; National Lipid Association Statin Safety Task Force Liver Expert Panel

doi:10.1016/j.amjcard.2005.12.014

An assessment of statin safety by hepatologists

Am J Cardiol. 2006 Apr 17;97(8A):77C-81C. doi: 10.1016/j.amjcard.2005.12.014. Epub 2006 Feb 3.

Authors

David E Cohen¹, Frank A Anania, Naga Chalasani; National Lipid Association Statin Safety Task Force Liver Expert Panel

Affiliation

¹ Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. dcohen@partners.org

PMID: 16581333
DOI: 10.1016/j.amjcard.2005.12.014

Abstract

The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

Publication types

Practice Guideline

MeSH terms

Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Contraindications
Evidence-Based Medicine
Fatty Liver / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Liver / enzymology
Liver Failure / chemically induced*
Liver Function Tests
Liver Transplantation

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aspartate Aminotransferases
Alanine Transaminase